Sign in or create an account to add this stock to your watchlist.
About Spark Therapeutics (NASDAQ:ONCE)
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of CLN2 disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONCE
CUSIPN/A
Phone888-772-7560
Debt
Debt-to-Equity RatioN/A
Current Ratio11.37
Quick Ratio11.27
Price-To-Earnings
Trailing P/E Ratio-10.27
Forward P/E Ratio-22.85
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.07 million
Price / Sales242.83
Cash FlowN/A
Price / CashN/A
Book Value$12.83 per share
Price / Book6.11
Profitability
EPS (Most Recent Fiscal Year)($7.63)
Net Income$-253,480,000.00
Net Margins-935.38%
Return on Equity-51.76%
Return on Assets-42.28%
Miscellaneous
Employees315
Outstanding Shares37,390,000
Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions
What is Spark Therapeutics' stock symbol?
Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."
How were Spark Therapeutics' earnings last quarter?
Spark Therapeutics Inc (NASDAQ:ONCE) announced its earnings results on Tuesday, May, 8th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($0.45) by $0.80. The biotechnology company had revenue of $15.68 million for the quarter, compared to analyst estimates of $51.55 million. Spark Therapeutics had a negative net margin of 935.38% and a negative return on equity of 51.76%. The firm's revenue was up 1134.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.70) earnings per share. View Spark Therapeutics' Earnings History.
What price target have analysts set for ONCE?
21 analysts have issued 12 month price targets for Spark Therapeutics' shares. Their predictions range from $40.00 to $113.00. On average, they expect Spark Therapeutics' share price to reach $76.10 in the next twelve months. View Analyst Ratings for Spark Therapeutics.
What are Wall Street analysts saying about Spark Therapeutics stock?
Here are some recent quotes from research analysts about Spark Therapeutics stock:
- 1. Raymond James analysts commented, "We are maintaining our Outperform rating for Spark. Hemophilia (WFH) 2018 World Congress, the company, along with its partner, Pfizer, provided an update on the ongoing Phase I/II study evaluating SPK-9001 for hemophilia B (Hem B). In addition, Spark’s competitor, BioMarin, provided an update on the ongoing Phase I/II trial of valoctocogene roxaparvovec (or BMN 270) in severe hemophilia A (Hem A)." (5/23/2018)
- 2. Mizuho analysts commented, "We expect the update to be an important catalyst given the large market opportunity in this indication. We expect to see data from three-dose cohorts and a longer follow-up time since the last update at the Hematology (ASH) in December 2017. Management is also advancing preparations for a phase 3 trial in parallel." (5/8/2018)
- 3. Cantor Fitzgerald analysts commented, "Updates to our Model. We are increasing our PT to $103/share from $100, based on the adjustment to our estimate of 2018 YE net cash. This increase is driven by a year-end cash increase from $549 million to $659 million ($18/ share), which accounts for the $110 million increase (a $3/share increase)." (4/30/2018)
Who are some of Spark Therapeutics' key competitors?
Some companies that are related to Spark Therapeutics include bluebird bio (BLUE), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), Bio-Techne (TECH), CRISPR Therapeutics (CRSP), arGEN-X BV (ARGX), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI) and Repligen (RGEN).
Who are Spark Therapeutics' key executives?
Spark Therapeutics' management team includes the folowing people:
- Mr. Jeffrey D. Marrazzo M.B.A., M.P.A., Co-Founder, CEO & Director (Age 39)
- Dr. Katherine A. High, Co-Founder, Pres and Chief Scientific Officer (Age 66)
- Mr. Stephen W. Webster, Chief Financial Officer (Age 57)
- Mr. John Furey, Chief Operating Officer (Age 53)
- Mr. Daniel R. Faga, Chief Bus. Officer (Age 38)
When did Spark Therapeutics IPO?
(ONCE) raised $88 million in an initial public offering on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.
Has Spark Therapeutics been receiving favorable news coverage?
News coverage about ONCE stock has been trending somewhat positive this week, Accern reports. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spark Therapeutics earned a media sentiment score of 0.13 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.97 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Spark Therapeutics' major shareholders?
Spark Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.08%), Federated Investors Inc. PA (4.02%), Rock Springs Capital Management LP (1.67%), Sofinnova Ventures Inc (1.29%), OppenheimerFunds Inc. (1.14%) and Rockefeller Capital Management L.P. (0.96%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics.
Which major investors are selling Spark Therapeutics stock?
ONCE stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Wells Fargo & Company MN, Eventide Asset Management LLC, Element Capital Management LLC, SG Americas Securities LLC, Guggenheim Capital LLC, Jane Street Group LLC and BlackRock Inc.. Company insiders that have sold Spark Therapeutics company stock in the last year include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Insider Buying and Selling for Spark Therapeutics.
Which major investors are buying Spark Therapeutics stock?
ONCE stock was purchased by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Rockefeller Capital Management L.P., PointState Capital LP, Pinnacle Associates Ltd., OppenheimerFunds Inc., UBS Group AG, Point72 Asset Management L.P. and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Spark Therapeutics.
How do I buy shares of Spark Therapeutics?
Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spark Therapeutics' stock price today?
One share of ONCE stock can currently be purchased for approximately $78.39.
How big of a company is Spark Therapeutics?
Spark Therapeutics has a market capitalization of $2.95 billion and generates $12.07 million in revenue each year. The biotechnology company earns $-253,480,000.00 in net income (profit) each year or ($7.63) on an earnings per share basis. Spark Therapeutics employs 315 workers across the globe.
How can I contact Spark Therapeutics?
Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]
MarketBeat Community Rating for Spark Therapeutics (ONCE)
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Spark Therapeutics (NASDAQ:ONCE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
21 Wall Street analysts have issued ratings and price targets for Spark Therapeutics in the last 12 months. Their average twelve-month price target is $76.10, suggesting that the stock has a possible downside of 2.92%. The high price target for ONCE is $113.00 and the low price target for ONCE is $40.00. There are currently 1 sell rating, 7 hold ratings and 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.57 | 2.70 | 2.75 | 2.83 |
| Ratings Breakdown: | 1 Sell Rating(s)
7 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $76.10 | $71.8947 | $69.8421 | $91.5294 |
| Price Target Upside: | 2.92% downside | 11.67% downside | 36.04% upside | 31.96% upside |
Spark Therapeutics (NASDAQ:ONCE) Consensus Price Target History
Spark Therapeutics (NASDAQ:ONCE) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Spark Therapeutics (NASDAQ:ONCE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Spark Therapeutics (NASDAQ ONCE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.90%
Spark Therapeutics (NASDAQ ONCE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/20/2018 | John Furey | COO | Sell | 6,723 | $82.50 | $554,647.50 | 6,723 |  |
| 4/18/2018 | John Furey | COO | Sell | 13,277 | $82.52 | $1,095,618.04 | 2,277 | |
| 4/12/2018 | John Furey | COO | Sell | 20,000 | $77.51 | $1,550,200.00 | 20,000 | |
| 12/11/2017 | John Furey | COO | Sell | 18 | $46.33 | $833.94 | | |
| 12/8/2017 | John Furey | COO | Buy | 18 | $73.48 | $1,322.64 | | |
| 11/28/2017 | Katherine A High | Insider | Sell | 5,000 | $71.32 | $356,600.00 | 215,000 | |
| 11/16/2017 | Stephen W Webster | CFO | Sell | 10,000 | $70.14 | $701,400.00 | 12,500 | |
| 11/13/2017 | Barge Joseph La | Insider | Sell | 5,500 | $71.44 | $392,920.00 | 8,146 | |
| 11/13/2017 | Jeffrey D Marrazzo | CEO | Sell | 20,000 | $71.54 | $1,430,800.00 | 250,000 | |
| 11/9/2017 | Barge Joseph La | Insider | Sell | 3,309 | $71.31 | $235,964.79 | 8,146 | |
| 10/31/2017 | Katherine A High | Insider | Sell | 5,000 | $83.30 | $416,500.00 | 215,000 | |
| 10/24/2017 | Daniel Faga | Insider | Sell | 7,500 | $80.96 | $607,200.00 | 6,000 | |
| 10/20/2017 | Daniel Faga | Insider | Sell | 6,000 | $79.95 | $479,700.00 | 6,000 | |
| 9/26/2017 | Katherine A High | Insider | Sell | 5,000 | $86.16 | $430,800.00 | 215,000 | |
| 9/21/2017 | Hospital Of Philade Children's | Director | Sell | 1,000,000 | $84.63 | $84,630,000.00 | 3,928,707 | |
| 9/19/2017 | Daniel Faga | Insider | Sell | 1,500 | $85.00 | $127,500.00 | 1,500 | |
| 9/12/2017 | Daniel Faga | Insider | Sell | 6,000 | $82.50 | $495,000.00 | 6,000 | |
| 9/7/2017 | Daniel Faga | Insider | Sell | 3,000 | $85.02 | $255,060.00 | 3,000 | |
| 9/5/2017 | Barge Joseph La | Insider | Sell | 5,500 | $81.00 | $445,500.00 | 10,825 | |
| 8/29/2017 | Katherine A High | Insider | Sell | 10,000 | $80.25 | $802,500.00 | 220,000 | |
| 8/23/2017 | Jeffrey D Marrazzo | CEO | Sell | 21,350 | $80.01 | $1,708,213.50 | 251,350 | |
| 8/15/2017 | Stephen W Webster | CFO | Sell | 10,000 | $79.38 | $793,800.00 | 12,500 | |
| 8/11/2017 | Jeffrey D Marrazzo | CEO | Sell | 15,000 | $75.10 | $1,126,500.00 | 245,000 | |
| 8/2/2017 | Jeffrey D Marrazzo | CEO | Sell | 28,650 | $80.01 | $2,292,286.50 | 258,650 | |
| 7/31/2017 | Stephen W Webster | CFO | Sell | 2,337 | $71.12 | $166,207.44 | 4,837 | |
| 7/25/2017 | Katherine A High | Insider | Sell | 10,000 | $72.53 | $725,300.00 | 220,000 | |
| 7/24/2017 | Anand Mehra | Director | Sell | 211,858 | $70.15 | $14,861,838.70 | | |
| 7/24/2017 | Daniel Faga | Insider | Sell | 3,000 | $70.00 | $210,000.00 | 3,000 | |
| 7/5/2017 | Jeffrey D Marrazzo | CEO | Sell | 5,669 | $65.00 | $368,485.00 | 235,669 | |
| 6/29/2017 | Daniel Faga | Insider | Sell | 4,500 | $62.71 | $282,195.00 | 4,500 | |
| 6/27/2017 | Katherine A High | Insider | Sell | 10,000 | $60.96 | $609,600.00 | 220,000 | |
| 6/21/2017 | Anand Mehra | Director | Sell | 6,302 | $65.00 | $409,630.00 | | |
| 6/21/2017 | Jeffrey D Marrazzo | CEO | Sell | 9,331 | $65.00 | $606,515.00 | 230,534 | |
| 6/19/2017 | Katherine A High | Insider | Sell | 10,000 | $60.00 | $600,000.00 | 220,000 | |
| 6/19/2017 | Stephen W Webster | CFO | Sell | 7,663 | $60.00 | $459,780.00 | 10,163 | |
| 6/7/2017 | Barge Joseph La | General Counsel | Sell | 5,000 | $55.00 | $275,000.00 | 9,567 | |
| 4/25/2017 | Katherine A High | Insider | Sell | 15,000 | $55.33 | $829,950.00 | 212,060 | |
| 4/25/2017 | Stephen W Webster | CFO | Sell | 10,000 | $55.18 | $551,800.00 | 4,398 | |
| 4/24/2017 | Katherine A High | Insider | Sell | 2,060 | $55.01 | $113,320.60 | 212,060 | |
| 4/24/2017 | Stephen W Webster | CFO | Sell | 1,898 | $55.00 | $104,390.00 | 4,398 | |
| 4/3/2017 | Barge Joseph La | General Counsel | Sell | 5,000 | $52.73 | $263,650.00 | 10,325 | |
| 3/1/2017 | Anand Mehra | Director | Sell | 84,654 | $65.02 | $5,504,203.08 | | |
| 3/1/2017 | Barge Joseph La | General Counsel | Sell | 5,000 | $64.41 | $322,050.00 | 10,325 | |
| 2/28/2017 | Anand Mehra | Director | Sell | 25,274 | $65.02 | $1,643,315.48 | | |
| 2/27/2017 | Anand Mehra | Director | Sell | 41,910 | $65.02 | $2,724,988.20 | | |
| 2/16/2017 | Anand Mehra | Director | Sell | 35,347 | $65.03 | $2,298,615.41 | | |
| 2/7/2017 | Anand Mehra | Director | Sell | 25,334 | $65.06 | $1,648,230.04 | | |
| 12/16/2016 | Anand Mehra | Director | Sell | 349,656 | $53.46 | $18,692,609.76 | | |
| 12/15/2016 | Barge Joseph La | Insider | Sell | 3,000 | $52.98 | $158,940.00 | 8,325 | |
| 12/13/2016 | Anand Mehra | Director | Sell | 122,532 | $55.17 | $6,760,090.44 | | |
| 11/14/2016 | Katherine A High | Insider | Sell | 10,000 | $60.30 | $603,000.00 | 210,000 | |
| 10/17/2016 | Jeffrey D Marrazzo | CEO | Sell | 5,000 | $54.66 | $273,300.00 | 235,000 | |
| 10/3/2016 | Barge Joseph La | Insider | Sell | 3,000 | $60.14 | $180,420.00 | 8,325 | |
| 9/16/2016 | Jeffrey D Marrazzo | CEO | Sell | 10,000 | $62.68 | $626,800.00 | 240,000 | |
| 9/15/2016 | Katherine A High | Insider | Sell | 10,000 | $60.37 | $603,700.00 | 220,500 | |
| 8/16/2016 | Hospital Of Philade Children's | Director | Sell | 1,000,000 | $60.90 | $60,900,000.00 | 5,768,707 | |
| 8/11/2016 | Anand Mehra | Director | Sell | 29,963 | $60.13 | $1,801,675.19 | | |
| 8/11/2016 | Jeffrey D Marrazzo | CEO | Sell | 16,970 | $60.04 | $1,018,878.80 | 236,971 | |
| 8/10/2016 | Katherine A High | Insider | Sell | 1,890 | $60.00 | $113,400.00 | 240,000 | |
| 8/8/2016 | Anand Mehra | Director | Sell | 100 | $60.47 | $6,047.00 | | |
| 8/8/2016 | Jeffrey D Marrazzo | CEO | Sell | 900 | $60.24 | $54,216.00 | 230,100 | |
| 8/8/2016 | Katherine A High | Insider | Sell | 500 | $60.24 | $30,120.00 | 242,290 | |
| 8/4/2016 | Anand Mehra | Director | Sell | 5,064 | $60.00 | $303,840.00 | | |
| 8/3/2016 | Jeffrey D Marrazzo | CEO | Sell | 16,530 | $60.02 | $992,130.60 | 242,348 | |
| 8/3/2016 | Katherine A High | Insider | Sell | 17,610 | $60.02 | $1,056,952.20 | 246,017 | |
| 8/1/2016 | Anand Mehra | Director | Sell | 22,665 | $60.03 | $1,360,579.95 | | |
| 8/1/2016 | Jeffrey D Marrazzo | CEO | Sell | 12,348 | $60.03 | $741,250.44 | 242,348 | |
| 8/1/2016 | Katherine A High | Insider | Sell | 13,983 | $60.02 | $839,259.66 | 246,017 | |
| 7/18/2016 | Jeffrey D Marrazzo | CEO | Sell | 5,000 | $52.53 | $262,650.00 | 235,000 | |
| 7/15/2016 | Coelho Rogerio Vivaldi | Insider | Sell | 7,000 | $53.03 | $371,210.00 | 19,716 | |
| 7/5/2016 | Barge Joseph La | Insider | Sell | 3,000 | $52.24 | $156,720.00 | 8,325 | |
| 6/20/2016 | Hospital Of Philade Children's | Major Shareholder | Sell | 1,000,000 | $42.30 | $42,300,000.00 | 6,768,707 | |
| 6/15/2016 | Jeffrey D Marrazzo | CEO | Sell | 5,000 | $46.49 | $232,450.00 | 235,000 | |
| 5/31/2016 | Anand Mehra | Director | Sell | 500 | $60.00 | $30,000.00 | | |
| 5/23/2016 | Katherine A High | Insider | Sell | 10,000 | $54.42 | $544,200.00 | 270,100 | |
| 5/20/2016 | Barge Joseph La | Insider | Sell | 10,000 | $47.65 | $476,500.00 | 12,825 | |
| 5/20/2016 | Stephen W Webster | CFO | Sell | 20,000 | $50.39 | $1,007,800.00 | 22,500 | |
| 5/19/2016 | Jeffrey D Marrazzo | CEO | Sell | 25,000 | $46.01 | $1,150,250.00 | 255,000 | |
| 4/21/2016 | Coelho Rogerio Vivaldi | Insider | Sell | 7,000 | $40.02 | $280,140.00 | 19,716 | |
| 12/28/2015 | Hospital Of Philade Children's | Major Shareholder | Sell | 131,505 | $44.18 | $5,809,890.90 | 7,768,707 | |
| 12/21/2015 | Hospital Of Philade Children's | Major Shareholder | Sell | 1,000,000 | $44.18 | $44,180,000.00 | 7,900,212 | |
| 12/1/2015 | Katherine A High | Insider | Sell | 10,000 | $55.31 | $553,100.00 | 280,000 | |
| 11/27/2015 | Anand Mehra | Director | Sell | 22,961 | $60.01 | $1,377,889.61 | | |
| 11/16/2015 | Katherine A High | Insider | Sell | 10,000 | $53.77 | $537,700.00 | 290,000 | |
| 11/12/2015 | Anand Mehra | Director | Sell | 130,605 | $60.11 | $7,850,666.55 | | |
| 10/14/2015 | Katherine A. High | insider | Sell | 30,000 | $49.34 | $1,480,200.00 | 300,000 | |
| 10/13/2015 | Katherine A. High | insider | Sell | 10,000 | $48.00 | $480,000.00 | 300,000 | |
| 10/12/2015 | Jeffrey D. Marrazzo | CEO | Sell | 75,000 | $48.35 | $3,626,250.00 | 230,000 | |
| 10/9/2015 | Jeffrey D. Marrazzo | CEO | Sell | 75,000 | $47.82 | $3,586,500.00 | 305,000 | |
| 10/8/2015 | Anand Mehra | Director | Sell | 529,544 | $45.46 | $24,073,070.24 | | |
| 10/7/2015 | Coelho Rogerio Vivaldi | insider | Sell | 41,000 | $48.85 | $2,002,850.00 | 5,383 | |
| 10/7/2015 | Stephen W. Webster | CFO | Sell | 20,000 | $48.86 | $977,200.00 | 2,500 | |
| 10/7/2015 | Steven Altschuler | Director | Buy | 5,000 | $49.11 | $245,550.00 | 5,000 | |
| 2/4/2015 | Anand Mehra | Director | Buy | 225,000 | $23.00 | $5,175,000.00 | | |
| 2/4/2015 | Hospital Of Philade Children's | Major Shareholder | Buy | 100,000 | $23.00 | $2,300,000.00 | | |
| 2/4/2015 | Stephen W Webster | CFO | Buy | 2,500 | $23.00 | $57,500.00 | | |
(Data available from 1/1/2013 forward)
Spark Therapeutics (NASDAQ ONCE) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Wired News - Spark Therapeutics and Pfizer Announced Positive Data from Phase-1/2 Clinical Trial of SPK-9001 for Haemophilia B Treatment
finance.yahoo.com - May 24 at 8:39 AM |
 | Cantor Fitzgerald Research Analysts Raise Earnings Estimates for Spark Therapeutics (ONCE)
www.americanbankingnews.com - May 24 at 8:34 AM |
| Spark Therapeutics (ONCE) Given Buy Rating at Raymond James
www.americanbankingnews.com - May 23 at 1:01 PM |
| Spark, Pfizer report progress on gene therapy for hemophilia
finance.yahoo.com - May 22 at 5:16 PM |
| Spark Therapeutics (ONCE) Given a $103.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 22 at 9:45 AM |
 | Spark's gene therapy SPK-9001 shows treatment benefit in hemophilia B study
seekingalpha.com - May 22 at 8:10 AM |
| Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
finance.yahoo.com - May 22 at 8:10 AM |
| Brokerages Expect Spark Therapeutics (ONCE) Will Post Quarterly Sales of $42.61 Million
www.americanbankingnews.com - May 19 at 3:02 AM |
| Brokerages Expect Spark Therapeutics (ONCE) Will Announce Earnings of -$0.39 Per Share
www.americanbankingnews.com - May 17 at 1:14 PM |
 | Pennsylvania’s Amish community is caught in a bind
www.msn.com - May 14 at 9:55 AM |
| Research Analysts Offer Predictions for Spark Therapeutics' Q2 2018 Earnings (ONCE)
www.americanbankingnews.com - May 14 at 2:00 AM |
| High Growth AMEX Stocks For The Day
finance.yahoo.com - May 12 at 5:19 PM |
| Jefferies Group Weighs in on Spark Therapeutics' Q2 2018 Earnings (ONCE)
www.americanbankingnews.com - May 11 at 8:35 AM |
| Recent Developments, Recommendations for JAZZ in May
finance.yahoo.com - May 10 at 5:15 PM |
| Spark Therapeutics (ONCE) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 10 at 1:43 PM |
| Edited Transcript of ONCE earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 8:41 AM |
| Q2 2018 EPS Estimates for Spark Therapeutics (ONCE) Raised by Analyst
www.americanbankingnews.com - May 10 at 6:36 AM |
| Q2 2018 Earnings Estimate for Spark Therapeutics (ONCE) Issued By Leerink Swann
www.americanbankingnews.com - May 10 at 6:36 AM |
| Spark Therapeutics (ONCE) Receives Underperform Rating from Wedbush
www.americanbankingnews.com - May 9 at 6:59 PM |
| BMO Capital Markets Increases Spark Therapeutics (ONCE) Price Target to $78.00
www.americanbankingnews.com - May 9 at 6:03 PM |
| Stifel Nicolaus Increases Spark Therapeutics (ONCE) Price Target to $76.00
www.americanbankingnews.com - May 9 at 4:43 PM |
| Royal Bank of Canada Boosts Spark Therapeutics (ONCE) Price Target to $75.00
www.americanbankingnews.com - May 9 at 3:12 PM |
| Spark Therapeutics (ONCE) Earns Overweight Rating from Barclays
www.americanbankingnews.com - May 9 at 1:29 PM |
| Q3 2018 EPS Estimates for Spark Therapeutics Boosted by Analyst (ONCE)
www.americanbankingnews.com - May 9 at 7:56 AM |
| Cowen Reaffirms "Buy" Rating for Spark Therapeutics (ONCE)
www.americanbankingnews.com - May 8 at 9:15 PM |
| Spark Therapeutics (ONCE) Given "Buy" Rating at Mizuho
www.americanbankingnews.com - May 8 at 5:27 PM |
| Spark Therapeutics' (ONCE) CEO Jeff Marrazzo on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:21 PM |
| Spark Therapeutics (ONCE) Given a $103.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 8 at 3:28 PM |
| Spark Therapeutics (ONCE) Posts Earnings Results, Misses Estimates By $0.80 EPS
www.americanbankingnews.com - May 8 at 9:34 AM |
| Spark Therapeutics misses by $0.84, misses on revenue
seekingalpha.com - May 8 at 8:40 AM |
| Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress
finance.yahoo.com - May 8 at 8:40 AM |
| Spark Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:40 AM |
| Spark Therapeutics' (ONCE) "Market Perform" Rating Reiterated at Leerink Swann
www.americanbankingnews.com - May 7 at 2:58 PM |
 | 16 Stocks Moving In Monday's Pre-Market Session
www.benzinga.com - May 7 at 9:26 AM |
| $53.82 Million in Sales Expected for Spark Therapeutics (ONCE) This Quarter
www.americanbankingnews.com - May 2 at 5:36 AM |
| Spark Therapeutics (ONCE) PT Raised to $63.00
www.americanbankingnews.com - May 1 at 10:42 AM |
| Spark Therapeutics (ONCE) Now Covered by Citigroup
www.americanbankingnews.com - May 1 at 9:08 AM |
| Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA COMMS, Westinghouse Air Brake Technologies, and Resource Capital — What Drives Growth in Today's Competitive Landscape
finance.yahoo.com - May 1 at 8:08 AM |
| Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights
finance.yahoo.com - May 1 at 8:08 AM |
| Mizuho Reaffirms Buy Rating for Spark Therapeutics (ONCE)
www.americanbankingnews.com - May 1 at 6:36 AM |
| Spark Therapeutics (ONCE) PT Set at $103.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 30 at 11:08 AM |
| Voucher sale brings $110M payday for Spark Therapeutics
finance.yahoo.com - April 30 at 9:50 AM |
| Spark Therapeutics Sells Priority Review Voucher for $110 Million
finance.yahoo.com - April 30 at 9:50 AM |
| -$0.45 Earnings Per Share Expected for Spark Therapeutics (ONCE) This Quarter
www.americanbankingnews.com - April 30 at 1:16 AM |
| John Furey Sells 6,723 Shares of Spark Therapeutics (ONCE) Stock
www.americanbankingnews.com - April 24 at 7:32 PM |
 | Portland's Casey Eye Institute enlists ground-breaking gene therapy
www.bizjournals.com - April 23 at 5:03 PM |
| Spark Therapeutics (ONCE) Downgraded by Chardan Capital
www.americanbankingnews.com - April 23 at 8:12 AM |
| Spark Therapeutics' ground-breaking gene therapy now being administered at select hospitals
www.bizjournals.com - April 20 at 8:33 AM |
| Spark Therapeutics' ground-breaking gene therapy now being administered at select hospitals
finance.yahoo.com - April 20 at 8:33 AM |
| Insider Selling: Spark Therapeutics (ONCE) COO Sells 13,277 Shares of Stock
www.americanbankingnews.com - April 19 at 7:19 PM |
Spark Therapeutics (NASDAQ:ONCE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Spark Therapeutics (NASDAQ:ONCE) Income Statement, Balance Sheet and Cash Flow Statement
Spark Therapeutics (NASDAQ ONCE) Stock Chart for Saturday, May, 26, 2018
Loading chart…
